|
1.
|
Olendzki BC, Leung K, Van Buskirk S, Reed G, Zurier RB. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evid Based Complement Alternat Med. 2011; 2011:827286.
|
|
|
|
|
2.
|
Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009 Mar; 11(1):109-19.
|
|
|
|
|
3.
|
Zurier RB, Sun YP, George KL, Stebulis JA, Rossetti RG, Skulas A, Judge E, Serhan CN. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J. 2009 May; 23(5):1503-9.
|
|
|
|
|
4.
|
Stebulis JA, Johnson DR, Rossetti RG, Burstein SH, Zurier RB. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008 Nov 7; 83(19-20):666-70.
|
|
|
|
|
5.
|
Han GM, O'Neil-Andersen NJ, Zurier RB, Lawrence DA. CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008 May-Jun; 253(1-2):92-101.
|
|
|
|
|
6.
|
George KL, Saltman LH, Stein GS, Lian JB, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol. 2008 Mar; 214(3):714-20.
|
|
|
|
|
7.
|
Parker J, Atez F, Rossetti RG, Skulas A, Patel R, Zurier RB. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol Int. 2008 May; 28(7):631-5.
|
|
|
|
|
8.
|
Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem. 2007 Jun 22; 282(25):18625-33.
|
|
|
|
|
9.
|
Burstein SH, Adams JK, Bradshaw HB, Fraioli C, Rossetti RG, Salmonsen RA, Shaw JW, Walker JM, Zipkin RE, Zurier RB. Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg Med Chem. 2007 May 15; 15(10):3345-55.
|
|
|
|
|
10.
|
Pedersen-Lane JH, Zurier RB, Lawrence DA. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. J Leukoc Biol. 2007 Apr; 81(4):934-41.
|
|
|
|
|
11.
|
Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. J Cell Biochem. 2007 Jan 1; 100(1):184-90.
|
|
|
|
|
12.
|
Stebulis JA, Rossetti RG, Atez FJ, Zurier RB. Fibroblast-like synovial cells derived from synovial fluid. J Rheumatol. 2005 Feb; 32(2):301-6.
|
|
|
|
|
13.
|
Burstein S, Zurier RB. Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. Arthritis Rheum. 2004 Dec; 50(12):4078-9; author reply 4079-80.
|
|
|
|
|
14.
|
Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci. 2004 Aug 6; 75(12):1513-22.
|
|
|
|
|
15.
|
Zurier RB. Prostaglandins: then and now and next. Semin Arthritis Rheum. 2003 Dec; 33(3):137-9.
|
|
|
|
|
16.
|
Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol. 2003 Aug; 108(2):95-102.
|
|
|
|
|
17.
|
Liu J, Li H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol. 2003 May; 63(5):983-92.
|
|
|
|
|
18.
|
Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem. 2003 Feb 15; 88(3):462-6.
|
|
|
|
|
19.
|
Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol. 2003 Feb 15; 65(4):649-55.
|
|
|
|
|
20.
|
Walker NJ, Zurier RB. Liver abnormalities in rheumatic diseases. Clin Liver Dis. 2002 Nov; 6(4):933-46.
|
|
|
|
|
21.
|
Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurier RB. Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol. 2002 Oct 1; 64(7):1147-50.
|
|
|
|
|
22.
|
Furse RK, Rossetti RG, Seiler CM, Zurier RB. Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, modulates interleukin-1beta production by human monocytes. J Clin Immunol. 2002 Mar; 22(2):83-91.
|
|
|
|
|
23.
|
Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R, Litofsky NS, Burstein S. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol. 2001 Sep 15; 62(6):755-63.
|
|
|
|
|
24.
|
Furse RK, Rossetti RG, Zurier RB. Gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, blocks amplification of IL-1 beta production by human monocytes. J Immunol. 2001 Jul 1; 167(1):490-6.
|
|
|
|
|
25.
|
Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin Clin Nutr Metab Care. 2001 Mar; 4(2):115-21.
|
|
|
|
|
26.
|
Burstein SH, Rossetti RG, Yagen B, Zurier RB. Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat. 2000 Apr; 61(1-2):29-41.
|
|
|
|
|
27.
|
DeLuca P, Rossetti RG, Alavian C, Karim P, Zurier RB. Effects of gammalinolenic acid on interleukin-1 beta and tumor necrosis factor-alpha secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo. J Investig Med. 1999 May; 47(5):246-50.
|
|
|
|
|
28.
|
Zurier RB, Rossetti RG, Seiler CM, Laposata M. Human peripheral blood T lymphocyte proliferation after activation of the T cell receptor: effects of unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun; 60(5-6):371-5.
|
|
|
|
|
29.
|
Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 1998 Jan; 41(1):163-70.
|
|
|
|
|
30.
|
Rothman D, Allen H, Herzog L, Pilapil A, Seiler CM, Zurier RB. Effects of unsaturated fatty acids on interleukin-1beta production by human monocytes. Cytokine. 1997 Dec; 9(12):1008-12.
|
|
|
|
|
31.
|
Rossetti RG, Seiler CM, DeLuca P, Laposata M, Zurier RB. Oral administration of unsaturated fatty acids: effects on human peripheral blood T lymphocyte proliferation. J Leukoc Biol. 1997 Oct; 62(4):438-43.
|
|
|
|
|
32.
|
Vassilopoulos D, Zurier RB, Rossetti RG, Tsokos GC. Gammalinolenic acid and dihomogammalinolenic acid suppress the CD3-mediated signal transduction pathway in human T cells. Clin Immunol Immunopathol. 1997 Jun; 83(3):237-44.
|
|
|
|
|
33.
|
Soscia PN, Zurier RB. Antirheumatic drug therapy during pregnancy. Bull Rheum Dis. 1997 Apr; 46(2):2-4.
|
|
|
|
|
34.
|
Zurier RB, Rossetti RG, Jacobson EW, DeMarco DM, Liu NY, Temming JE, White BM, Laposata M. gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum. 1996 Nov; 39(11):1808-17.
|
|
|
|
|
35.
|
Zurier RB, DeMarco DM, Liu NY. Treatment of rheumatoid arthritis. N Engl J Med. 1996 Sep 12; 335(11):822; author reply 822-3.
|
|
|
|
|
36.
|
Williams WV, Rosenbaum H, Zurier RB. Effects of unsaturated fatty acids on expression of early response genes in human T lymphocytes. Pathobiology. 1996; 64(1):27-31.
|
|
|
|
|
37.
|
Rothman D, DeLuca P, Zurier RB. Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Semin Arthritis Rheum. 1995 Oct; 25(2):87-96.
|
|
|
|
|
38.
|
Rossetti RG, Seiler CM, Laposata M, Zurier RB. Differential regulation of human T lymphocyte protein kinase C activity by unsaturated fatty acids. Clin Immunol Immunopathol. 1995 Sep; 76(3 Pt 1):220-4.
|
|
|
|
|
39.
|
DeLuca P, Rothman D, Zurier RB. Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 1995 Aug; 21(3):759-77.
|
|
|
|
|
40.
|
Karikó K, Rosenbaum H, Kuo A, Zurier RB, Barnathan ES. Stimulatory effect of unsaturated fatty acids on the level of plasminogen activator inhibitor-1 mRNA in cultured human endothelial cells. FEBS Lett. 1995 Mar 13; 361(1):118-22.
|
|
|
|
|
41.
|
DeMarco DM, Santoli D, Zurier RB. Effects of fatty acids on proliferation and activation of human synovial compartment lymphocytes. J Leukoc Biol. 1994 Nov; 56(5):612-5.
|
|
|
|
|
42.
|
Tate GA, Zurier RB. Suppression of monosodium urate crystal-induced inflammation by black currant seed oil. Agents Actions. 1994 Nov; 43(1-2):35-8.
|
|
|
|
|
43.
|
Rossetti RG, Brathwaite K, Zurier RB. Suppression of acute inflammation with liposome associated prostaglandin E1. Prostaglandins. 1994 Sep; 48(3):187-95.
|
|
|
|
|
44.
|
Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol. 1994 Sep; 33(9):847-52.
|
|
|
|
|
45.
|
Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med. 1993 Nov 1; 119(9):867-73.
|
|
|
|
|
46.
|
Zurier RB. Fatty acids, inflammation and immune responses. Prostaglandins Leukot Essent Fatty Acids. 1993 Jan; 48(1):57-62.
|
|
|
|
|
47.
|
Williams WV, Fang Q, Demarco D, VonFeldt J, Zurier RB, Weiner DB. Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. J Clin Invest. 1992 Aug; 90(2):326-33.
|
|
|
|
|
48.
|
Lee AH, Ramanujam T, Ware P, Edelstein PH, Brooks JJ, Freundlich B, Schumacher HR, Zurier RB, Weiner DB, Williams WV. Molecular diagnosis of Ureaplasma urealyticum septic arthritis in a patient with hypogammaglobulinemia. Arthritis Rheum. 1992 Apr; 35(4):443-8.
|
|
|
|
|
49.
|
Louthrenoo W, Zager EL, Freundlich B, Zurier RB. Intravenous corticosteroid therapy of cervical cord compression in rheumatoid arthritis. Clin Exp Rheumatol. 1992 Mar-Apr; 10(2):173-5.
|
|
|
|
|
50.
|
Soscia PN, Zurier RB. Drug therapy of rheumatic diseases during pregnancy. Bull Rheum Dis. 1992; 41(2):1-3.
|
|
|
|
|
51.
|
Borofsky MA, Zurier RB, Rosenbaum H, Weiner DB, Williams WV. Effects of polyunsaturated fatty acids on interleukin-2-dependent T cell growth. Immunol Res. 1992; 11(2):154-64.
|
|
|
|
|
52.
|
Murphy NG, Zurier RB. Treatment of rheumatoid arthritis. Curr Opin Rheumatol. 1991 Jun; 3(3):441-8.
|
|
|
|
|
53.
|
Callegari PE, Zurier RB. Botanical lipids: potential role in modulation of immunologic responses and inflammatory reactions. Rheum Dis Clin North Am. 1991 May; 17(2):415-25.
|
|
|
|
|
54.
|
DeMarco D, Kunkel SL, Strieter RM, Basha M, Zurier RB. Interleukin-1 induced gene expression of neutrophil activating protein (interleukin-8) and monocyte chemotactic peptide in human synovial cells. Biochem Biophys Res Commun. 1991 Jan 31; 174(2):411-6.
|
|
|
|
|
55.
|
Zurier RB. Role of prostaglandins E in inflammation and immune responses. Adv Prostaglandin Thromboxane Leukot Res. 1991; 21B:947-53.
|
|
|
|
|
56.
|
Zurier RB. Prostaglandin E1: is it useful? J Rheumatol. 1990 Nov; 17(11):1439-41.
|
|
|
|
|
57.
|
Pullman-Mooar S, Laposata M, Lem D, Holman RT, Leventhal LJ, DeMarco D, Zurier RB. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. Arthritis Rheum. 1990 Oct; 33(10):1526-33.
|
|
|
|
|
58.
|
Zurier RB. Conventional drug therapies and complications, novel therapies, and nondrug treatments. Curr Opin Rheumatol. 1990 Jun; 2(3):463-8.
|
|
|
|
|
59.
|
Leventhal LJ, DeMarco DM, Zurier RB. Antinuclear antibody in pericardial fluid from a patient with primary cardiac lymphoma. Arch Intern Med. 1990 May; 150(5):1113-5.
|
|
|
|
|
60.
|
Santoli D, Phillips PD, Colt TL, Zurier RB. Suppression of interleukin 2-dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGE-independent mechanism of inhibition by the fatty acids. J Clin Invest. 1990 Feb; 85(2):424-32.
|
|
|
|
|
61.
|
Baker DG, Krakauer KA, Tate G, Laposata M, Zurier RB. Suppression of human synovial cell proliferation by dihomo-gamma-linolenic acid. Arthritis Rheum. 1989 Oct; 32(10):1273-81.
|
|
|
|
|
62.
|
Santoli D, Zurier RB. Prostaglandin E precursor fatty acids inhibit human IL-2 production by a prostaglandin E-independent mechanism. J Immunol. 1989 Aug 15; 143(4):1303-9.
|
|
|
|
|
63.
|
Tate G, Mandell BF, Laposata M, Ohliger D, Baker DG, Schumacher HR, Zurier RB. Suppression of acute and chronic inflammation by dietary gamma linolenic acid. J Rheumatol. 1989 Jun; 16(6):729-34.
|
|
|
|
|
64.
|
Tate GA, Mandell BF, Karmali RA, Laposata M, Baker DG, Schumacher HR, Zurier RB. Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid. Arthritis Rheum. 1988 Dec; 31(12):1543-51.
|
|
|
|
|
65.
|
Whittum-Hudson J, Ballow M, Zurier RB. Effect of PGE1 treatment on in vitro thymocyte function of normal and autoimmune mice. Immunopharmacology. 1988 Sep-Oct; 16(2):71-8.
|
|
|
|
|
66.
|
Tate GA, Mandell BF, Schumacher HR, Zurier RB. Suppression of acute inflammation by 15 methyl prostaglandin E1. Lab Invest. 1988 Aug; 59(2):192-9.
|
|
|
|
|
67.
|
Zurier RB, Kozma M, Sinnett-Smith J, Rozengurt E. Vasoactive intestinal peptide synergistically stimulates DNA synthesis in mouse 3T3 cells: role of cAMP, Ca2+, and protein kinase C. Exp Cell Res. 1988 May; 176(1):155-61.
|
|
|
|
|
68.
|
Makover D, Freundlich B, Zurier RB. Relapse of systemic lupus erythematosus in a patient receiving cyclosporine A. J Rheumatol. 1988 Jan; 15(1):117-9.
|
|
|
|
|
69.
|
Dore-Duffy P, Guha A, Rothman BL, Zurier RB. Synthesis of prostaglandin E by peritoneal macrophages from NZB/W mice. Life Sci. 1988; 42(26):2669-76.
|
|
|
|
|
70.
|
Bomalaski JS, Alvarez J, Touchstone J, Zurier RB. Alteration of uptake and distribution of eicosanoid precursor fatty acids by aspirin. Biochem Pharmacol. 1987 Oct 1; 36(19):3249-53.
|
|
|
|
|
71.
|
Kelly CJ, Zurier RB, Krakauer KA, Blanchard N, Neilson EG. Prostaglandin E1 inhibits effector T cell induction and tissue damage in experimental murine interstitial nephritis. J Clin Invest. 1987 Mar; 79(3):782-9.
|
|
|
|
|
72.
|
Krakauer KA, Williamson PK, Baker DG, Zurier RB. Separation and quantification of prostaglandins E1 and E2 as their panacyl derivatives using reverse phase high pressure liquid chromatography. Prostaglandins. 1986 Aug; 32(2):301-10.
|
|
|
|
|
73.
|
Dore-Duffy P, Zurier RB. Lymphocyte adherence in multiple sclerosis: role of the cytoskeleton and prostaglandin E. Prostaglandins Leukot Med. 1986 Aug; 23(2-3):277-87.
|
|
|
|
|
74.
|
Bomalaski JS, Goldstein CS, Dailey AT, Douglas SD, Zurier RB. Uptake of fatty acids and their mobilization from phospholipids in cultured monocyte-macrophages from rheumatoid arthritis patients. Clin Immunol Immunopathol. 1986 May; 39(2):198-212.
|
|
|
|
|
75.
|
Bomalaski JS, Clark MA, Zurier RB. Enhanced phospholipase activity in peripheral blood monocytes from patients with rheumatoid arthritis. Arthritis Rheum. 1986 Mar; 29(3):312-8.
|
|
|
|
|
76.
|
Bomalaski JS, Clark MA, Douglas SD, Zurier RB. Enhanced phospholipase A2 and C activities of peripheral blood polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Leukoc Biol. 1985 Nov; 38(5):649-54.
|
|
|
|
|
77.
|
Baker DG, Baumgarten DF, Bomalaski JS, Zurier RB. Cyclic adenosine 3'5' monophosphate stimulates prostaglandin E production by human adherent synovial cells. Prostaglandins. 1985 Oct; 30(4):669-82.
|
|
|
|
|
78.
|
Whittum J, Goldschneider I, Greiner D, Zurier R. Developmental abnormalities of terminal deoxynucleotidyl transferase positive bone marrow cells and thymocytes in New Zealand mice: effects of prostaglandin E1. J Immunol. 1985 Jul; 135(1):272-80.
|
|
|
|
|
79.
|
Sedgwick JB, Berube ML, Zurier RB. Stimulus-dependent inhibition of superoxide generation by prostaglandins. Clin Immunol Immunopathol. 1985 Feb; 34(2):205-15.
|
|
|
|
|
80.
|
Elias JA, Zurier RB, Schreiber AD, Leff JA, Daniele RP. Monocyte inhibition of lung fibroblast growth: relationship to fibroblast prostaglandin production and density-defined monocyte subpopulations. J Leukoc Biol. 1985 Jan; 37(1):15-28.
|
|
|
|
|
81.
|
Elias JA, Rossman MD, Zurier RB, Daniele RP. Human alveolar macrophage inhibition of lung fibroblast growth. A prostaglandin-dependent process. Am Rev Respir Dis. 1985 Jan; 131(1):94-9.
|
|
|
|
|
82.
|
Elias JA, Zurier RB, Rossman MD, Berube ML, Daniele RP. Inhibition of lung fibroblast growth by human lung mononuclear cells. Am Rev Respir Dis. 1984 Nov; 130(5):810-6.
|
|
|
|
|
83.
|
Goldstein CS, Bomalaski JS, Zurier RB, Neilson EG, Douglas SD. Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients. Kidney Int. 1984 Nov; 26(5):733-40.
|
|
|
|
|
84.
|
Dore-Duffy P, Berube ML, Siok C, Zurier RB. Oral administration of prostaglandin E2 to humans: effects on peripheral blood leukocyte function. J Lab Clin Med. 1984 Aug; 104(2):283-91.
|
|
|
|
|
85.
|
Freundlich B, Trinchieri G, Perussia B, Zurier RB. The cytotoxic effector cells in preparations of adherent mononuclear cells from human peripheral blood. J Immunol. 1984 Mar; 132(3):1255-60.
|
|
|
|
|
86.
|
Bomalaski JS, Williamson PK, Zurier RB. Prostaglandins and the inflammatory response. Clin Lab Med. 1983 Dec; 3(4):695-717.
|
|
|
|
|
87.
|
Dore-Duffy P, Zurier RB. Lymphocyte adherence in multiple sclerosis: lack of virus specificity. Cell Immunol. 1983 Apr 15; 77(2):215-21.
|
|
|
|
|
88.
|
Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB. Antinuclear antibodies in multiple sclerosis. Arch Neurol. 1982 Aug; 39(8):504-6.
|
|
|
|
|
89.
|
Zurier RB. Prostaglandins, immune responses, and murine lupus. Arthritis Rheum. 1982 Jul; 25(7):804-9.
|
|
|
|
|
90.
|
Kunkel SL, Ogawa H, Conran PB, Ward PA, Zurier RB. Suppression of acute and chronic inflammation by orally administered prostaglandins. Arthritis Rheum. 1981 Sep; 24(9):1151-8.
|
|
|
|
|
91.
|
Dore-Duffy P, Zurier RB. Lymphocyte adherence in multiple sclerosis. Role of monocytes and increased sensitivity of MS lymphocytes to prostaglandin E. Clin Immunol Immunopathol. 1981 Jun; 19(3):303-13.
|
|
|
|
|
92.
|
Dore-Duffy P, Koff TS, Zurier RB. Adherence of human peripheral blood lymphocytes to virus infected cells: role of the cytoskeleton and prostaglandin E. Prostaglandins Med. 1981 Mar; 6(3):299-307.
|
|
|
|
|
93.
|
Kunkel SL, Ogawa H, Ward PA, Zurier RB. Suppression of chronic inflammation by evening primrose oil. Prog Lipid Res. 1981; 20:885-8.
|
|
|
|
|
94.
|
Kunkel SL, Fantone JC, Ward PA, Zurier RB. Modulation of inflammatory reactions by prostaglandins. Prog Lipid Res. 1981; 20:633-40.
|
|
|
|
|
95.
|
Fantone JC, Kunkel SL, Ward PA, Zurier RB. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J Immunol. 1980 Dec; 125(6):2591-6.
|
|
|
|
|
96.
|
Adelman N, Ksiazek J, Cohen S, Yoshida T, Zurier RB. Prostaglandin E1 treatment of NBZ/W F1 hybrids--induction of in vitro and in vivo cell-mediated immune response to DNA. Clin Immunol Immunopathol. 1980 Nov; 17(3):353-62.
|
|
|
|
|
97.
|
Zurier RB. Prostaglandins. Their potential in clinical medicine. Postgrad Med. 1980 Sep; 68(3):70-81.
|
|
|
|
|
98.
|
Zurier RB. SLE and motherhood. J Rheumatol. 1980 Sep-Oct; 7(5):591-3.
|
|
|
|
|
99.
|
Krakauer KA, Zurier RB. Pinocytosis in human synovial cells in vitro. Evidence for enhanced activity in rheumatoid arthritis. J Clin Invest. 1980 Sep; 66(3):592-8.
|
|
|
|
|
100.
|
Zurier RB, Gionfriddo M, Miller P. Treatment of NZB/W ("lupus") mice with 15(S)-15 methyl PGE1. Prostaglandins Med. 1980 Apr; 4(4):281-4.
|
|
|
|
|
101.
|
Dore-Duffy P, Zurier RB. E-rosette formation in multiple sclerosis. Adv Prostaglandin Thromboxane Res. 1980; 8:1685-9.
|
|
|
|
|
102.
|
Zurier RB. Cyclic nucleotides and the Chediak-Higashi syndrome. Adv Cyclic Nucleotide Res. 1980; 12:173-9.
|
|
|
|
|
103.
|
Kunkel SL, Thrall RS, Kunkel RG, McCormick JR, Ward PA, Zurier RB. Suppression of immune complex vasculitis in rats by prostaglandin. J Clin Invest. 1979 Nov; 64(5):1525-9.
|
|
|
|
|
104.
|
Zurier RB. Systemic lupus erythematosus. Hosp Pract. 1979 Aug; 14(8):45-54.
|
|
|
|
|
105.
|
Dore-Duffy P, Zurier RB. E-rosette formation in normals and patients with multiple sclerosis: effect of prostaglandin and aspirin. Clin Immunol Immunopathol. 1979 Jul; 13(3):261-8.
|
|
|
|
|
106.
|
Abeles M, Belin DC, Zurier RB. Eosinophilic fasciitis: a clinicopathologic study. Arch Intern Med. 1979 May; 139(5):586-8.
|
|
|
|
|
107.
|
Dore-Duffy P, Zurier RB, Donaldson J, Nystrom SS, Viola MV, Rothman B, Thompson HG. Lymphocyte adherence in multiple sclerosis. Neurology. 1979 Feb; 29(2):232-5.
|
|
|
|
|
108.
|
Dore-Duffy P, Zurier RB. Lymphocyte adherence in multiple sclerosis: effect of aspirin. J Clin Invest. 1979 Jan; 63(1):154-7.
|
|
|
|
|
109.
|
Krakauer KA, Torrey SB, Zurier RB. Prostaglandin E1 treatment of NZB/W mice. III. Preservation of spleen cell concentrations and mitogen-induced proliferative responses. Clin Immunol Immunopathol. 1978 Nov; 11(3):256-66.
|
|
|
|
|
110.
|
Zurier RB. Prostaglandins and cyclic nucleotides in the Chédiak-Higashi syndrome and experimental systemic lupus erythematosus. J Invest Dermatol. 1978 Jul; 71(1):36-9.
|
|
|
|
|
111.
|
Zurier RB, Argyros TG, Urman JD, Warren J, Rothfield NF. Systemic lupus erythematosus. Management during pregnancy. Obstet Gynecol. 1978 Feb; 51(2):178-80.
|
|
|
|
|
112.
|
Zurier RB. Lysosomes and dermatology. Int J Dermatol. 1977 Nov; 16(9):726-35.
|
|
|
|
|
113.
|
Zurier RB, Damjanov I, Sayadoff DM, Rothfield NF. Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis. Arthritis Rheum. 1977 Nov-Dec; 20(8):1449-56.
|
|
|
|
|
114.
|
Zurier RB, Dore-Duffy P, Viola MV. Adherence of human peripheral blood lymphycytes to measles-infected cells. Enhancement by prostaglandin E1. N Engl J Med. 1977 Jun 23; 296(25):1443-6.
|
|
|
|
|
115.
|
Urman JD, Zurier RB, Rothfield NF. Reiter's syndrome associated with champylobacter fetus infection. Ann Intern Med. 1977 Apr; 86(4):444-5.
|
|
|
|
|
116.
|
Zurier RB, Sayadoff DM, Torrey AB, Rothfield NF. Prostaglandin E treatment of NZB/NZW mice. Arthritis Rheum. 1977 Mar; 20(2):723-8.
|
|
|
|
|
117.
|
Zurier RB, Doty J, Goldenberg A. Cyclic AMP response to prostaglandin E1 in mononuclear cells from peripheral blood and synovial fluid of patients with rheumatoid arthritis. Prostaglandins. 1977 Jan; 13(1):25-31.
|
|
|
|
|
118.
|
Oliver JM, Zurier RB. Correction of characteristic abnormalities of microtubule function and granule morphology in Chediak-Higashi syndrome with cholinergic agonists. J Clin Invest. 1976 May; 57(5):1239-47.
|
|
|
|
|
119.
|
Zurier RB. Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus. Arthritis Rheum. 1976 Jan-Feb; 19(1):73-8.
|
|
|
|
|
120.
|
Zurier RB. Prostaglandin release from human polymorphonuclear leukocytes. Adv Prostaglandin Thromboxane Res. 1976; 2:815-8.
|
|
|
|
|
121.
|
Notani GW, Kenyon AJ, Zurier RB. Altered neutrophil function induced by serum from patients with systemic lupus erythematosus. Adv Exp Med Biol. 1976; 73 Pt B:147-54.
|
|
|
|
|
122.
|
Zurier RB. The potential role of prostaglandins in skeletal and muscular disorders. Ann Clin Lab Sci. 1975 Jul-Aug; 5(4):276-81.
|
|
|
|
|
123.
|
Zurier RB. Rheumatoid disease, an overview. Conn Med. 1975 Jun; 39(6):348-53.
|
|
|
|
|
124.
|
Oliver JM, Zurier RB, Berlin RD. Concanavalin a cap formation on polymorphonuclear leukocytes of normal and beige (chediak-higashi) mice. Nature. 1975 Feb 6; 253(5491):471-3.
|
|
|
|
|
125.
|
Hoffstein S, Zurier RB, Weissmann G. Mechanisms of lysosomal enzyme release from human leucocytes. III. Quantitative morphologic evidence for an effect of cyclic nucleotides and colchicine on degranulation. Clin Immunol Immunopathol. 1974 Nov; 3(2):201-17.
|
|
|
|
|
126.
|
Zurier RB, Weissmann G, Hoffstein S, Kammerman S, Tai HH. Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function. J Clin Invest. 1974 Jan; 53(1):297-309.
|
|
|
|
|
127.
|
Zurier RB. Prostaglandins, inflammation, and asthma. Arch Intern Med. 1974 Jan; 133(1):101-10.
|
|
|
|
|
128.
|
Weissmann G, Zurier RB, Hoffstein S. Leukocytes as secretory organs of inflammation. Agents Actions. 1973 Dec; 3(5):370-9.
|
|
|
|
|
129.
|
Zurier RB, Weissman G. Anti-immunologic and anti-inflammatory effects of steroid therapy. Med Clin North Am. 1973 Sep; 57(5):1295-307.
|
|
|
|
|
130.
|
Zurier RB, Mitnick H, Bloomgarden D, Weissmann G. Effect of bee venom on experimental arthritis. Ann Rheum Dis. 1973 Sep; 32(5):466-70.
|
|
|
|
|
131.
|
Zurier RB, Hoffstein S, Weissmann G. Suppression of acute and chronic inflammation in adrenalectomized rats by pharmacologic amounts of prostaglandins. Arthritis Rheum. 1973 Sep-Oct; 16(5):606-18.
|
|
|
|
|
132.
|
Zurier RB, Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from human leukocytes. I. Effect of cyclic nucleotides and colchicine. J Cell Biol. 1973 Jul; 58(1):27-41.
|
|
|
|
|
133.
|
Bourne HR, Lehrer RI, Lichtenstein LM, Weissmann G, Zurier R. Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest. 1973 Mar; 52(3):698-708.
|
|
|
|
|
134.
|
Zurier RB, Ballas M. Prostaglandin E 1 (PGE 1 ) suppression of adjuvant arthritis. Histopathology. Arthritis Rheum. 1973 Mar-Apr; 16(2):251-7.
|
|
|
|
|
135.
|
Zurier RB, Hoffstein S, Weissmann G. Cytochalasin B: effect on lysosomal enzyme release from human leukocytes. Proc Natl Acad Sci U S A. 1973 Mar; 70(3):844-8.
|
|
|
|
|
136.
|
Weissmann G, Zurier RB, Hoffstein S. Leukocytic proteases and the immunologic release of lysosomal enzymes. Am J Pathol. 1972 Sep; 68(3):539-64.
|
|
|
|
|
137.
|
Zurier RB, Quagliata F. Effect of prostaglandin E 1 on adjuvant arthritis. Nature. 1971 Dec 3; 234(5327):304-5.
|
|
|
|
|
138.
|
Weissmann G, Zurier RB, Spieler PJ, Goldstein IM. Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med. 1971 Sep 1; 134(3 Pt 2):149s-165s.
|
|
|
|
|
139.
|
Weissmann G, Zurier RB, Spieler PJ, Goldstein IM. Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J Exp Med. 1971 Sep 1; 134(3):149-65.
|
|
|
|
|
140.
|
Weissmann G, Dukor P, Zurier RB. Effect of cyclic AMP on release of lysosomal enzymes from phagocytes. Nat New Biol. 1971 Jun 2; 231(22):131-5.
|
|
|
|
|
141.
|
Zurier RB, Patterson JF, Levitanr . Relationship between net water absorption and hexanoic acid absorption from the intact human jejunum. Am J Dig Dis. 1968 Feb; 13(2):109-12.
|
|
|
|
|
142.
|
Zurier RB, Campbell RG, Hashim SA, Van Itallie TB. Enrichment of depot fat with odd and even numbered medium chain fatty acids. Am J Physiol. 1967 Feb; 212(2):291-4.
|
|
|
|
|
143.
|
Zurier RB, Campbell RG, Hashim SA, Van Itallie TB. Use of medium-chain triglyceride in management of patients with massive resection of the small intestine. N Engl J Med. 1966 Mar 3; 274(9):490-3.
|
|
|
|
|
144.
|
Zurier RB, Hashim SA, Van Itallie TB. Effect of medium chain triglyceride on cholestyramine-induced steatorrhea in man. Gastroenterology. 1965 Nov; 49(5):490-5.
|
|
|
|
